Memento Medicines Raises $93M Series A to Advance Retinal Disease Therapy

Memento Medicines, a Boston-based biotechnology company focused on retinal diseases, has raised $93M in Series A funding. The round was led by Forbion, RA Capital Management, and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital. The company's lead asset, MMT-205, is a bispecific antibody designed to activate Tie2 while inhibiting VEGF, targeting retinal diseases including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

The financing follows Memento Medicines' acquisition of global rights to MMT-205 through an exclusive licensing agreement with Curacle Co., Ltd. and MabTics Co., Ltd.. The company plans to use the capital to advance IND-enabling studies and move the therapy toward clinical development. The significance extends beyond a single financing event, reflecting growing investor appetite for differentiated ophthalmology assets and highlighting how capital continues to flow toward programs that combine validated biology with a clear development path.

What Happened

Biotech financing has become a strange spectator sport. Capital is available, but only for companies that can answer uncomfortable questions before investors ask them. Memento Medicines appears to have done exactly that. The Boston-based company announced a $93M Series A in June 2026 to advance its lead retinal disease program, MMT-205. The round attracted a syndicate that reads like a who's who of life sciences investing: Forbion, RA Capital Management, Avego BioScience Capital, Sanofi Ventures, and Samsara BioCapital.

Leading the company is Naveen Daryani, CEO of Memento Medicines, who now finds himself steering one of the more closely watched ophthalmology startups launched this year. At the center of the story is MMT-205, formerly known as MT-103. Memento secured exclusive global rights to the asset through a licensing agreement with Curacle Co., Ltd. and MabTics Co., Ltd.. In startup terms, this wasn't a company searching for a product; it was a company built around one. Many biotech startups begin by raising capital and then constructing a pipeline, but Memento Medicines entered the market with a lead program, a development thesis, and investors willing to underwrite the journey.

Why This Matters

Retinal disease is one of those healthcare categories that rarely dominates headlines but quietly affects millions of lives. Patients with neovascular age-related macular degeneration and diabetic macular edema are not looking for marginal improvements in convenience; they are trying to preserve vision, independence, and quality of life. Current standards of care have created massive markets around VEGF inhibition, but diseases involving vascular instability often involve multiple pathways interacting simultaneously.

That is where MMT-205 enters the conversation. The therapy combines Tie2 activation and VEGF inhibition in a single bispecific antibody. Tie2 plays an important role in maintaining vascular stability, making it a compelling target alongside VEGF in retinal disease. Investors clearly believe the dual-target approach deserves serious attention. Biology is filled with examples of diseases that looked straightforward until researchers discovered they weren't, and retinal disease has been one of the most important proving grounds for that lesson. For broader context on retinal diseases, the National Eye Institute provides extensive research and patient resources on conditions such as AMD and diabetic eye disease.

Market Context

The biotech market of 2026 is rewarding precision. A few years ago, companies could often raise significant rounds based on platform narratives and broad promises. Today's investors increasingly want tangible assets, clear development plans, and mechanisms they can understand without requiring interpretive dance from a pitch deck. Memento Medicines fits that pattern with a defined therapeutic focus, a licensed lead asset, experienced healthcare investors, and a clear development roadmap.

Boston remains one of the world's most active biotechnology hubs, producing a steady pipeline of venture-backed therapeutics companies. That ecosystem continues to attract founders, researchers, investors, and pharmaceutical partners looking for the next generation of medicines. Ophthalmology has also emerged as an attractive specialty for investors because clinical endpoints are measurable, regulatory pathways are established, and successful therapies can generate meaningful commercial outcomes.

Competitive Landscape

The retinal disease market is not lacking competition. VEGF-targeting therapies have shaped modern ophthalmology, creating significant commercial opportunities and improving outcomes for countless patients. Any new entrant must demonstrate why physicians, regulators, and patients should care. Memento Medicines is betting that dual-pathway biology can create that differentiation.

Rather than relying solely on VEGF inhibition, MMT-205 combines VEGF suppression with Tie2 activation, potentially addressing vascular dysfunction from multiple angles. Whether that ultimately translates into superior clinical outcomes remains a question for future studies. What investors appear to be funding today is not certainty; they are funding a hypothesis supported by compelling biology and a development strategy worth pursuing.

What This Signals

Several signals emerge from the financing. First, large early-stage biotech rounds remain available when investors see a credible path forward. Second, ophthalmology continues to attract institutional capital despite broader uncertainty across venture markets. Third, licensing strategies are becoming increasingly important. Instead of spending years generating assets internally, companies are increasingly forming around promising programs sourced through licensing agreements. Memento Medicines represents a textbook example of that model.

The company effectively launched with a meaningful asset already in hand. Curacle previously disclosed potential licensing economics exceeding $1B through a combination of upfront payments, milestone payments, and royalties tied to MMT-205. While licensing economics and company valuation are very different metrics, the figure highlights the level of belief surrounding the asset's long-term potential.

The Bigger Industry Shift

The deeper story isn't the $93M. It's what the $93M represents. Biotech investing is becoming more disciplined, not less ambitious. Investors still want transformative therapies and category-defining companies, but what has changed is the burden of proof. Companies increasingly need to arrive with stronger scientific rationale, clearer development plans, and assets capable of surviving rigorous scrutiny. Memento Medicines appears to have met that standard.

The company now moves into the next phase: IND-enabling studies, clinical development preparation, and eventually the harder task of translating scientific promise into clinical evidence. Funding announcements generate headlines, but clinical results create companies. The retinal disease market will ultimately decide where Memento Medicines lands on that spectrum.